Ongentys opicapone

Drug Class

Catechol-O-methyltransferase (COMT) inhibitor

Mechanism

Opicapone is a peripheral, selective, and reversible catechol-O-methyltransferase (COMT) inhibitor that decreases the degradation of levodopa, thereby increasing levodopa levels in the brain.

Approved Indication

Adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing 'off' episodes.

What This Means For Patients

Ongentys is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2020) — Sources
• EMA — Approved (2016) — Sources

Pivotal Clinical Evidence

• BIPARK-I — Ferreira et al., Lancet Neurol 2016 (NCT01564927) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/ongentys
• https://www.gcs-web.com/